WO1991007489A1 - Bcr/abl transgenic animals as models for philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia - Google Patents
Bcr/abl transgenic animals as models for philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia Download PDFInfo
- Publication number
- WO1991007489A1 WO1991007489A1 PCT/US1990/006845 US9006845W WO9107489A1 WO 1991007489 A1 WO1991007489 A1 WO 1991007489A1 US 9006845 W US9006845 W US 9006845W WO 9107489 A1 WO9107489 A1 WO 9107489A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bcr
- abl
- gene
- exon
- leukemia
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 90
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 77
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 title claims abstract description 48
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 title claims abstract description 46
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 title claims abstract description 43
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 title claims abstract description 32
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 title claims abstract description 28
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 title claims abstract description 28
- 210000004214 philadelphia chromosome Anatomy 0.000 title abstract description 14
- 241000282414 Homo sapiens Species 0.000 claims abstract description 56
- 101150049556 Bcr gene Proteins 0.000 claims abstract description 53
- 208000032839 leukemia Diseases 0.000 claims abstract description 45
- 108700019146 Transgenes Proteins 0.000 claims abstract description 44
- 101150033421 ABL gene Proteins 0.000 claims abstract description 37
- 102100026008 Breakpoint cluster region protein Human genes 0.000 claims description 106
- 101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 claims description 87
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims description 84
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims description 83
- 210000004027 cell Anatomy 0.000 claims description 62
- 210000001185 bone marrow Anatomy 0.000 claims description 18
- 108700024394 Exon Proteins 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 238000010171 animal model Methods 0.000 claims description 7
- 210000002798 bone marrow cell Anatomy 0.000 claims description 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 2
- 230000000644 propagated effect Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 abstract description 19
- 206010000830 Acute leukaemia Diseases 0.000 abstract description 10
- 241000282412 Homo Species 0.000 abstract description 4
- 230000006698 induction Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000011820 transgenic animal model Methods 0.000 abstract description 3
- 238000011285 therapeutic regimen Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 35
- 108090000623 proteins and genes Proteins 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 20
- 238000000034 method Methods 0.000 description 19
- 241000699660 Mus musculus Species 0.000 description 17
- 239000012634 fragment Substances 0.000 description 17
- 238000011830 transgenic mouse model Methods 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 210000000265 leukocyte Anatomy 0.000 description 14
- 210000005259 peripheral blood Anatomy 0.000 description 14
- 239000011886 peripheral blood Substances 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 11
- 210000000349 chromosome Anatomy 0.000 description 10
- 230000001684 chronic effect Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000001613 neoplastic effect Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 108700025690 abl Genes Proteins 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 108700020796 Oncogene Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003622 mature neutrocyte Anatomy 0.000 description 6
- 210000000066 myeloid cell Anatomy 0.000 description 6
- 210000004872 soft tissue Anatomy 0.000 description 6
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 5
- 208000004860 Blast Crisis Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 235000013601 eggs Nutrition 0.000 description 5
- 230000005945 translocation Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 206010049146 Neck mass Diseases 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000013020 embryo development Effects 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 3
- 206010011906 Death Diseases 0.000 description 3
- 102000012153 HLA-B27 Antigen Human genes 0.000 description 3
- 108010061486 HLA-B27 Antigen Proteins 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 108010024221 Proto-Oncogene Proteins c-bcr Proteins 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000035578 autophosphorylation Effects 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 208000003747 lymphoid leukemia Diseases 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 210000001167 myeloblast Anatomy 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 2
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 241000364057 Peoria Species 0.000 description 2
- 208000032721 Philadelphia Chromosome Diseases 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 102000015690 Proto-Oncogene Proteins c-bcr Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 101001001642 Xenopus laevis Serine/threonine-protein kinase pim-3 Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 102000051878 human BCR Human genes 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000013383 initial experiment Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000001237 metamyelocyte Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003887 myelocyte Anatomy 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000003566 phosphorylation assay Methods 0.000 description 2
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 238000007900 DNA-DNA hybridization Methods 0.000 description 1
- 241001400238 Dictyostelium medium Species 0.000 description 1
- 241001453233 Doodia media Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010069360 Leukaemic infiltration Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 241000713883 Myeloproliferative sarcoma virus Species 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 208000007541 Preleukemia Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 101100457369 Rattus norvegicus Myl2 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 208000019513 White blood cell disease Diseases 0.000 description 1
- 238000010817 Wright-Giemsa staining Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 description 1
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- RCTYPNKXASFOBE-UHFFFAOYSA-M chloromercury Chemical compound [Hg]Cl RCTYPNKXASFOBE-UHFFFAOYSA-M 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 230000001456 gonadotroph Effects 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- XFQQGEMIPJZPMX-UHFFFAOYSA-N guanidine;isocyanatosulfanylimino(oxo)methane Chemical compound NC(N)=N.O=C=NSN=C=O XFQQGEMIPJZPMX-UHFFFAOYSA-N 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000002989 hepatic vein Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 102000055277 human IL2 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000002122 leukaemogenic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 108010065781 myosin light chain 2 Proteins 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000002330 subarachnoid space Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0381—Animal model for diseases of the hematopoietic system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
Definitions
- the present invention relates to transgenic non-human animals which contain a transgene comprising a BCR/ABL gene fusion and which develop leukemia.
- the nonhuman transgenic animals of the invention may serve as valuable models for chronic myelogenous and adult
- Leukemia is a malignant condition of white blood cells in which bone marrow is diffusely replaced by
- Leukemias may be classified as adult lymphocytic (or lymphoblastic), chronic lymphocytic, acute myelogenous, or chronic
- CML Chronic myelogenous leukemia
- Prognosis for survival is approximately three to four years.
- the clinical progression of CML may be divided into two phases, a chronic phase and a blastic phase
- the chronic phase there is a proliferation and accumulation of polymorphonuclear leukocytes and granulocytic (myeloid) cells of intermediate maturity; myeloblasts usually account for less than ten percent of cells in the bone marrow and peripheral blood.
- the chronic phase typically persists for a median of 36 to 40 months before the onset of the blastic phase.
- the blastic phase there is a dramatic increase in the number of undifferentiated cells. In about one third of CML blastic phase cases, the blast cell morphology has some of the characteristics of lymphoblasts, including expression of the enzyme terminal
- Acute lymphocytic (or lymphoblastic) leukemia accounts for about 20 percent of all leukemias, occurs predominantly in children, and develops more frequently inmales than in females. Untreated, the prognosis for survival is approximately four months; with treatment, survival may be for several years and some cures have been reported (Robbins and Angell, supra).
- the leukemic cells of about 75 percent of patients with ALL are often termed "null" cells because they lack B and T cell markers.
- the Philadelphia (Ph) chromosome is a cytogenetic hallmark of CML. It is the result of a reciprocal translocation t(9;22) (q34;q21) which is found specifically in the leukemic cells of over 95% of chronic myelogenous leukemia (CML) patients (Rowley, 1973, Nature 243:290-293; de Klein et al., 1982, Nature 300:765-767).
- ALL acute lymphocytic leukemia
- Both P210 and P190 contain all the amino acids of the ABL oncogene except those encoded by its first exon; they exhibit an abnormal tyrosme kmase activity and are strongly
- transgenic animals refers to non-human animals which have incorporated a foreign gene into their genome; because this gene is present in germline tissues, it is passed from parent to offspring. Exogenous genes are introduced into single-celled embryos (Brinster et al.,
- mice have been shown to express globin (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:6376-6380), transferrin (McKnight et al., 1983, Cell 34:335-341), immunoglobulm (Brinster et al., 1983, Nature 306:332-336;
- Transgenic animals have been observed to express deregulated oncogenes and develop tumors (Stewart et al., 1984, Cell 38: 627-637; Adams et al., 1985, Nature 318: 533-538; Hanahan, 1985, Nature 315: 115-122; Lacey et al.,
- transgenic animals have been developed as model systems for the study of white blood cell disorders.
- the pim-1 gene has been found to be activated by proviral insertion in murine leukemia virus-induced T cell lymphomas (Cuypress et al.,
- mice bearing a similar transgene were observed to develop B cell lymphomas at a later stage of development (Adams et al., 1985, Nature 318: 533-538).
- BCR/ABL was found not to transform NIH 3T3 fibroblasts (Daley et al., 1987, Science 237: 532-535).
- v-abl viral abl gene
- Oncogene Res. 3: 387-399 The synthetic fused gene was combined with either the immunoglobulin heavy chain gene enhancer or a portion of the long terminal repeat from myeloproliferative sarcoma virus (Franz et al., 1986, Proc.
- the present invention relates to non-human transgenic animals which contain a transgene comprising a BCR/ABL gene fusion and which develop leukemia.
- the transgenic animals may exhibit a rapid induction of acute leukemia or, alternatively, a chronic myelogenous-type leukemia.
- the transgenic animals of the invention carry a transgene which comprises a 5' portion of BCR exons and a 3' portion of ABL exons.
- the ABL nucleotide sequences comprise human ABL nucleotide sequences.
- the transgene comprises non-human abl gene sequences.
- transgene comprises either at least a complete third exon or a portion of the second exon of the ABL gene.
- the transgene comprises either at least a complete third exon or a portion of the second exon of the ABL gene.
- transgenic animals carry a transgene comprising the first exon of the BCR gene as well as at least one exon from the
- the transgenic animals carry a transgene comprising the first exon of the BCR gene and exons 2 through 11 of the ABL gene.
- the present invention offers the advantage of providing, for the first time, a non-human transgenic animal model system which carries the BCR/ABL gene fusion characteristic of the Philadelphia chromosome; transgenic animals of the invention have been found to develop
- CML chronic myelogenous leukemia
- ALL acute lymphoblastic leukemia
- ABL the human ABL oncogene using standard
- ABL as used herein may refer to human or non-human nucleotide sequence.
- abl non-human oncogene corresponding to ABL.
- BCR the Breakpoint Cluster Region gene.
- Mbcr the major breakpoint cluster region in which are located several of the breakpoints characteristic of the Philadelphia chromosome of CML.
- Transgenic animal a nonhuman animal which has incorporated a foreign gene into its genome.
- Transgene transgen ⁇ c sequence: a foreign gene or recombinant nucleic acid construct which has been incorporated into a transgenic animal,
- FIG. 1 Expression of P190 BCR/ABL.
- Two clones (lanes 1 and 2) transfected with P190/BCR produce a P190 protein, that is active in an in vitro
- FIG. 1 P190-producing BCR/ABL construct as comprised in pALMP. Boxed areas indicate the position of coding sequences; the location of the MT promoter, BCR exon
- ABL exon 2 and the main body of ABL exons is as
- Figure 3 (0.6 XhBg) is indicated above the map with a cross-hatched box. The arrows above the map point to the approximate locations of oligonucleotide primers, "ALL E” and "ALL F” (Kawasaki et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 85:5698-5702).
- B BamHI;
- RNAs used include those from heart, muscle, brain and spleen of mouse #509 (lanes 1-4); NIH 3T3 cells (lanes 6 and 8); control non-transgenic #417 RNA (lanes 7 and 10), NIH 3T3 cells transfected with P190/BCR (lane 9) and RNA from transgenic #418 (lane 11).
- FIG. 1 Pathology of CML, blast crisis mice.
- PMNs polymorphonuclear neutrophils
- x640, H and E lesser numbers of more undifferentiated forms
- FIG. 6 Pathology of ALL mice.
- Medium power view of involved bone marrow from mouse #509. Note the extensive involvement of marrow with primitive lymphoblasts with scant cytoplasm (x580, H and E).
- B. Medium power view of peritrabecular soft tissue. Note the extensive involvement of bone-associated soft tissue with primitive, neoplastic lymphoblasts which are invading between skeletal muscle fibers (x600, H and E).
- C. Medium power view of peripheral blood from mouse #538. Note the extensive involvement with primitive, neoplastic lymphoblasts which demonstrate primitive nuclear chromatin and scant cytoplasm (x620, Wright-Giemsa).
- Figure 7 Diagram of (a) BCR gene; (b) c-ABL gene; (c) a BCR/ABL gene fusuion on a Philadelphia
- FIG. 8 The BCR/ABL c18(der) construct as comprised in pCLMP.
- the open box represents the BCR gene coding sequences; the solid boxes represent ABL coding sequences.
- the present invention relates to transgenic non-human animals which carry a BCR/ABL transgene and whichmay serve as animal models of leukemia in humans.
- BCR/ABL transgene a BCR/ABL transgene
- the detailed description of the invention is divided into the following subsections:
- BCR and ABL genes may be produced using any method known in the art.
- BCR and ABL genes, or portions thereof, may be derived from human or non-human (abl) sources.
- BCR or ABL gene sequences may be obtained from the same species intended to serve as the transgenic host, although it may be preferable to use human BCR and ABL gene sequences to create a model for the gene product associated with human disease.
- the ABL gene may be obtained from constructs which have been the subjects of publication and are
- ABL sequences may also be used to identify additional clones bearing ABL sequences in genomic DNA or cDNA libraries using standard hybridization techniques such as the method set forth by Benton and Davis (1977, Science 196:180) for bacteriophage libraries and
- PCR polymerase chain reaction
- BCR sequences may be obtained from publicly available constructs or using the pALMP or pCLMP constructs of the present inventioo in conjunction with standard colony hybridization or PCR techniques.
- a naturally occurring BCR/ABL fused gene may be cloned from cells carrying the
- the BCR and ABL sequences utilized may represent genomic DNA or cDNA sequences. Portions of the BCR and ABL genes may be linked together using any technique known in the art, including the ligation of compatible restriction endonuclease
- the fused BCR/ABL construct may comprise the first BCR exon and either the entire third exon of ABL or a portion of its second exon (see Figure 7). If the ABL sequences are derived from human c-ABL sequences, the BCR/ABL construct may contain one or more ABL exons.
- the BCR/ABL gene fusion is engineered to resemble BCR/ABL gene fusions produced by naturally occurring translocations and found in association with Philadelphia chromosomes.
- the fused BCR/ABL gene may be engineered to resemble the BCR/ABL fusion found on Philadelphia chromosomes in patients with CML, and may preferably comprise the first BCR exon as well as at least one exon from the Mbcr region and the second through eleventh ABL exons of the ABL gene or a functional portion therof.
- a functional portion of the ABL gene is construed to refer to a portion of the ABL gene which encodes a protein which retains tyrosine kinase activity.
- a specific example of a construct which resembles a BCR/ABL fusion associated with CML is comprised in construct pCLMP of the prsent invention.
- the fused BCR/ABL gene may be engineered to resemble the
- the constructs of the invention may comprise one BCR exon and the second through eleventh ABL exons, or a functional portion thereof.
- a specific example of a construct which resembles a BCR/ABL fusion associated with ALL is comprises in construct pALMP of the present invention. According to the invention, when constructs which resemble naturally occurring BCR/ABL fusions associated with CML are used to create transgenic animals, the resulting transgenic animals may develop a leukemia similar to CML, and when constructs which resemble naturally occurring BCR/ABL fusions
- the resulting transgenic animals may be likely to develop a leukemia similar to ALL.
- the BCR/ABL gene fusion of the invention is preferably engineered to be under the control of a suitable promoter sequence.
- Any promoter sequence known in the art may be used, but it is preferable that the promoter used is not particularly active during embryonic development, as such promoters, including the BCR promoter, have been
- Suitable promoters would include inducible promoters, including, but not limited to, the metallothionine promoter (Brinster et al., 1982, Nature
- alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58); alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al, 1987, Genes and Devel.
- beta-globin gene control region which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48: 703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).
- the BCR/ABL gene constructs may be cloned using any method known in the art.
- a large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, cosmids, plasmids or modified viruses, but the vector system must be compatible with the host cell used.
- vectors inclde but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as PBR322, pVCs or Bluescript ® (Stratagene) plasmid derivatives. Recombinant molecules may be
- a BCR/ABL construct may preferably be tested to determine whether it results in a functional gene product.
- the BCR/ABL construct may be co-transfected into a suitable cell line (including but not limited to the Rat-2 cell line) together with an appropriate reporter gene (such as, but not limited to, thymidine kinase activity, resistance to antibiotics, including G418 etc.).
- a reporter gene such as, but not limited to, thymidine kinase activity, resistance to antibiotics, including G418 etc.
- Transfected cells may then be selected and tested for expression of a BCR/ABL gene product.
- RNA may be harvested from the cells and tested for the presence of a BCR/ABL mRNA transcript using either standard Northern blot techniques or
- the transfectants may be tested for acquisition of BCR/ABL associated tyrosine kinase activity using a standard in vitro phosphorylation assay, such as that described in Fainstein et al. (1987, Nature 330: 386-388) or tested for reactivity with anti-ABL antiserum, such as that described in Stam et al. (1987,
- protein may be harvested from the transformed cells and analyzed by
- the recombinant DNA molecules of the invention may be introduced into the genome of non-human animals using any method for generating transgenic animals known in the art.
- the scheme presently employed to produce transgenic mice involves the following: male and female mice, from a defined inbred genetic background, are mated at midnight. Twelve hours later, the female is sacrificed and the fertilized eggs are removed from the uterine tubes. At this time, the pronuclei have not yet fused and it is possible to visualize them in the light microscope. Foreign DNA is then microinjected (100-1000 molecules per egg) into a pronucleus. Shortly thereafter fusion of the pronuclei (a female pronucleus or the male pronucleus) occurs and, in some cases, foreign DNA inserts into (usually) one chromosome of the fertilized egg or zygote.
- the zygote is then implanted into a pseudo-pregnant female mouse (previously mated with a vasectomized male) where the embryo develops for the full gestation period of 20-21 days.
- the surrogate mother delivers these mice and by four weeks the pups are weaned from the mother.
- a portion of the tail (a dispensable organ) is removed and the DNA extracted.
- DNA-DNA hybridization (in a dot blot, slot blot or Southern blot test) is employed to determine whether the mice carry the foreign DNA.
- Of the eggs injected on average 10% develop properly and produce mice.
- Of the mice born, on average one in four (25%) are transgenic for an overall efficiency of 2.5%.
- mice carry tandemly repeated copies of the foreign gene (from 1-80 copies) at one chromosomal location or site.
- mice guinea pigs, rabbits and pigs, sheep, cows, goats, and horses, to name but a few, may provide useful transgenic systems.
- transgenic animals including but not limited to, microinjection, cell gun, transfection of DNA, and
- the present invention relates to the production of non-human transgenic animals that may serve as
- the transgenic animals of the invention provide, for the first time, an animal model system in which the BCR/ABL transgene results in the
- transgenic animals infra, in a specific embodiment of the invention, in which transgenic animals are produced which carry a BCR/ABL transgene that resembles the BCR/ABL gene fusion associatedwith Philadelphia chromosome positive ALL, the transgenic animals of the invention were observed to develop acute leukemia resembling ALL at an age comparable to the average age of onset of human ALL.
- the transgenic animals of the invention provide a useful system for the development of therapeutic programs for these diseases, including both chemotherapeutic and
- transgenic animals of the invention can be used to advance basic research in these diseases.
- transgenic animals which carry a BCR/ABL
- transgene may be produced, and the bone marrow of these transgenic animals may be harvested and then used to repopulate the bone marrow of another animal, the bone marrow of which has been destroyed (e.g. by x-ray
- Animals produced by this method may also be used as effective models of CML or AML, and offer the advantage of not expressing BCR/ABL in non-hematologic tissues.
- the BCR/ABL constructs may be
- bone marrow cells including, but not limited to, embryonic stem cells, of a non-human animal using any method known in the art (including transfection, transformation, infection, electroporation, microinjection or cell gun) in vivo or in vitro, and the cells may then be re-introduced so that they may re-populate the bone marrow of animal.
- the resulting animal should contain BCR/ABL sequences in the genomic DNA of some but not all of its cells, and therefore may be considered a chimeric animal.
- a useful model for the development of leukemia may be produced by generating a transgenic animal in which the BCR/ABL transgene is under the control of an inducible promoter.
- the BCR/ABL transgene may be under the control of the metallothionine promoter, such that when the
- transgenic animal is exposed to heavy metals, the
- BCR/ABL BCR/ABL expression of BCR/ABL may be induced and leukemia may result.
- transgenic animals of the invention may be used as sources of cells and tissues which may be grown in culture and which may be useful in the study of human leukemia. 6.
- EXAMPLE GENERATION OF BCR/ABL TRANSGENIC
- This construct contained all coding information for P190 under control of the BCR gene promoter.
- plasmid mMT-1 was digested with Sstl and Bglll and the 200 bp MT promoter fragment was inserted into pSK digested with Sstl and
- inserts (3 kb) were separated from the insert (14 kb) by an Sstll digestion; inserts were purified by electrophoresis on low melting point agarose gels, phenol/sodium acetate
- RNAs were isolated using guanidine- thioisocyanate (Chomczynski and Sacci, 1987, Anal. Biochem. 162:156-159). The first strand was synthesized using
- mice were anesthesized prior to all procedures possibly involving pain or discomfort. Mice were sacrificed using cardiac puncture; peripheral blood samples were collected from the tails of anesthesized mice. Tissue sections were fi.xed for
- WBC counts were performed with a hemocytometer.
- the construct further contains segments of BCR intron 1, the pSK polylinker, a segment of ABL intron 1, exon 2, intron 2 and the remaining ABL coding sequences.
- RNAs isolated from two animals which had exhibited distinct pathological symptoms (see below) were used to evaluate expression of the transgene.
- the oligonucleotides should amplify a cDNA fragment of 307 bp in cells containing the 7.0 kb BCR/ABL chimeric mRNA.
- NIH 3T3 control RNA (lanes 6 and 8). This indicates that the construct produces mRNA in the absence of intentional induction of the promoter with heavy metals. In the RNA of mouse #418, the 307 bp fragment is also clearly present
- RNA isolated post-morten from a non-transgenic sibling (#417, lane 7 and 10) showed no signal.
- peripheral blood The remaining animal, a pregnant female (mouse #528), died at 58 days while giving birth. It had aterminal blood cell count of 2.9 x 10 9 /L. A small but significant percentage (approximately 5%) of peripheral blood white cells were lymphoblasts. All eight animals which died were autopsied and examined histopathologically. Interestingly, six animals (#530, 509, 510, 538, 529 and528) were diagnosed as having ALL, while the remaining two ( #418 and 536 , both of which were found dead) were
- mice #418 demonstrated the presence of greatly enlarged neck masses (see Figure 5A), which proved histopathologically to be either lymph nodes and/or subcutaneous tissue involved with neoplastic
- myelogenous leukemia cells (see Figure 5C).
- the neck mass-associated leukemia cells were composed predominantly of primitive myeloid-type blasts (myeloblasts) with varying smaller numbers of promyleocytes, myelocytes and
- mouse #418 and 536 were diagnosed as having CML, blast crisis (myeloid type).
- WBC peripheral white blood cell count
- ND not done
- NA not applicable
- CML chronic myelogenous leukemia
- ALL acute lymphoblastic leukemia
- LL lymphoblastic lymphoma.
- mouse 523 and 540 are alive with normal WBC counts, a small but significant percentage (3-5%) of peripheral blood white cells were lymphoblasts. in contrast, mouse #509, 530, 510, 538, 529 and
- mice demonstrated peritrabecular invasion of neoplastic lymphoblasts into the surrounding skeletal muscle- containing soft tissues (Figure 6B). All mice
- mice #530, 509, 510, 538, 529) were easily diagnosed as having ALL.
- LL leukemia/lymphoblastic lymphoma
- CML chronic myelogenous
- PMNs polymorphonuclear neutrophils
- ALL acute lymphoblastic leukemia
- Ig immunoglobulin.
- genotypic evaluation of the ALL Mice is most likely consistent with the presence of a polyclonal population of neoplastic pre-B lymphoblasts.
- leukemia closely resembled the corresponding human disease.
- transgene (see Table I). It is interesting that both mice with single transgenic copies, although alive with normal WBC counts, have a small but significant percentage of circulating lymphoblasts on peripheral blood smears. It appears that the transgene was expressed in the two animals tested representing both types of acute leukemia (CML blast crisis and ALL), although we cannot quantitatively compare the levels in these animals using the PCR/RT method on RNAs of different quality. Transcription was found in the heart, brain, muscle, spleen and liver of mouse #509.
- RNA prepraration may therefore be due to the fact that the animal was sacrificed by cardiac puncture and removal of blood from this organ.
- the BCR gene which contributes its promoter to the chimeric BCR/ABL gene in human Ph-positive leukemia is not expressed exclusively or in extremely high levels in bone marrow (Collins et al., 1987, Mol. Cell Biol. 7:2810- 2876). The results presented here indicate, indeed, that its promoter is not necessary at all for leukemogenesis.
- BCR gene consists of its 5' coding sequences and that its fusion of these sequences to human ABL produces a unique, leukemogenic protein.
- the properties of this protein must be closely related to its primary structure; recently, mice have been generated which were transgenic for a BCR/v-ABL
- lymphoid and myeloid were generated in BCR/ABL transgenic mice, previous work in both man and mouse supports a close relationship between B-lymphoid and myeloid cells. It is well known that human chronic myelogenous leukemia often evolves to a pre-B lymphoblast crisis (Bakhsi et al., 1983,
- RAS oncogene-containing retroviruses coexpress pre-B and myeloid cell phenotypes suggesting that a progenitor cell for both B lymphocytes and myeloid cells (primarily
- pro G/M/B progenitor cell
- mice 10-13 days of age, it is possible that they may have been preleukemic in utero.
- the P190 fusion protein may therefore be involved in a very agressive type of leukemia with an early onset and rapid progression. Indeed, the association of the P190 protein with a more aggressive type of disease is supported by experiments, in which the effects of P190 and P210 on immature lymphoid cells were compared: P190 appears to stimulate the growth of immature lymphoid cells more strongly than the P210 in mouse bone marrow cultures (Mol. Cell Biol. 9:1866-1874).
- Ph-chromosome is often neither the sole nor the first chromosomal abnormality present in the leukemic cells of the patients (Dameshek and Gunz, 1983, in "The Nature of
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to non-human transgenic animals which contain a transgene comprising a BCR/ABL gene fusion and which develop leukemia. In a preferred embodiment of the present invention, the transgenic animals exhibit a rapid induction of acute leukemia. The present invention offers the advantage of providing, for the first time, a non-human transgenic animal model system which carries the BCR/ABL gene fusion characteristic of the Philadelphia chromosome and which develops leukemia in a manner directly analogous to the clinical progression of chronic myelogenous leukemia (CML) and/or acute lymphoblastic leukemia (ALL) in humans. This model system for human leukemia may be valuable in obtaining a better understanding of CML and ALL and in developing effective therapeutic regimens.
Description
BCR/ABL TRANSGENIC ANIMALS AS MODELS FOR
PHILADELPHIA CHROMOSOME POSITIVE CHRONIC
MYELOGENOUS AND ACUTE LYMPHOBLASTIC LEUKEMIA
1. INTRODUCTION
The present invention relates to transgenic non-human animals which contain a transgene comprising a BCR/ABL gene fusion and which develop leukemia. The nonhuman transgenic animals of the invention may serve as valuable models for chronic myelogenous and adult
lymphoblastic leukemia in humans. 2. BACKGROUND OF THE INVENTION
2.1. CHRONIC MYELOGENOUS AND ADULT
LYMPHOBLASTIC LEUKEMIA
Leukemia is a malignant condition of white blood cells in which bone marrow is diffusely replaced by
relatively immature white blood cells which generally also appear, in large numbers, in the circulating blood (Robbins and Angell, 1976, in "Basic Pathology", Second Edition, W.B. Saunders Co., Philadelphia, pp. 349-354). Leukemias may be classified as adult lymphocytic (or lymphoblastic), chronic lymphocytic, acute myelogenous, or chronic
myelogenous.
Chronic myelogenous leukemia (CML) accounts for approximately 25 percent of all leukemias. Onset of the disease occurs most frequently in middle age, with males and females affected approximately equally. CML is
generally associated with prominent enlargement of the spleen. Prognosis for survival is approximately three to four years.
The clinical progression of CML may be divided into two phases, a chronic phase and a blastic phase
(Canellos (1983) in "Harrison's Principles of Internal
Medicine", Petersdorf et al., eds., Tenth Edition, McGraw
Hill Book Company, N.Y., pp. 808-810). During the chronic phase, there is a proliferation and accumulation of
polymorphonuclear leukocytes and granulocytic (myeloid) cells of intermediate maturity; myeloblasts usually account for less than ten percent of cells in the bone marrow and peripheral blood. The chronic phase typically persists for a median of 36 to 40 months before the onset of the blastic phase. During the blastic phase, there is a dramatic increase in the number of undifferentiated cells. In about one third of CML blastic phase cases, the blast cell morphology has some of the characteristics of lymphoblasts, including expression of the enzyme terminal
deoxynucleotidyl transferase and reactivity with a non-B, non-T anti-acute lymphoblastic leukemia antiserum.
Acute lymphocytic (or lymphoblastic) leukemia accounts for about 20 percent of all leukemias, occurs predominantly in children, and develops more frequently inmales than in females. Untreated, the prognosis for survival is approximately four months; with treatment, survival may be for several years and some cures have been reported (Robbins and Angell, supra). The leukemic cells of about 75 percent of patients with ALL are often termed "null" cells because they lack B and T cell markers.
2.1.1. THE PHILADELPHIA CHROMOSOME
The Philadelphia (Ph) chromosome is a cytogenetic hallmark of CML. It is the result of a reciprocal translocation t(9;22) (q34;q21) which is found specifically in the leukemic cells of over 95% of chronic myelogenous leukemia (CML) patients (Rowley, 1973, Nature 243:290-293; de Klein et al., 1982, Nature 300:765-767).
In addition, it occurs in 25-30% of adult and 2-10% of pediatric patients with acute lymphocytic leukemia (ALL)
(Sandberg et al., 1980, Cancer Genet. Cytogenet. 2:145-174; Priest et al., 1980). The presence of the Philadelphia chromosome in ALL has been associated with a worse
prognosis, particularly in children (Robeiro et al., 1987, Blood 70: 948). The genes located at the breakpoints on both chromosomes have been identified; the ABL oncogene located at 9q34 is translocated to chromosome 22q11, where it is fused in a head-to-tail fashion to 5' exons of the
BCR gene (de Klein et al., 1982, Nature 300:765-767;
Heisterkamp et al., 1985, Nature 315:758-761; Shtivelman et al., 1985, Nature 315:550-554). In CML, the breakpoints on chromosome 22 are clustered within a small (5.8 kb) region (the major breakpoint cluster region, Mbcr) located in the middle of the BCR gene (Groffen et al., 1984, Cell 36:93- 99). In ALL, a heterogeneity with respect to the
breakpoints in the BCR gene exists (Rodenhuis et al., 1985, N. Engl. J. Med. 313:51-52; Erikson et al., 1986, Proc.
Natl. Acad. Sci. U.S.A. 83:1807-1811; de Klein et al.,
1986, Blood 68:1369-1375); some patients have a breakpoint within Mbcr, whereas in others, the break occurs within the first intron of the BCR gene (Heisterkamp et al., 1988, Nucl. Acids Res. 16:10069-10081; Hermans et al., 1987, Cell 51:33-40). The majority of pediatric Ph-positive ALL patients have a breakpoint of the latter type (Heisterkamp et al., 1989, Blood 73 : 1307-1311) . In all cases , the translocation results in the transcription of a chimeric BCR/ABL mRNA which is translated into a BCR/ABL fusion protein (for an overview, see: Kurzrock et al., 1988, N.
Engl. J. Med. 319:990-998).
Two distinct BCR/ABL fusion proteins have been identified; in CML and in adult Ph-positive ALL, a
phosphoprotein of 210,000 MW (P210) is found, which
contains a substantial amino-terminal BCR component
(Shtivelman et al., 1985, Nature 315:550-554; Mes-Masson et al., 1986, Proc. Natl. Acad. Sci. U.S.A. 83:9768-9772); the chimeric P190 protein found in juvenile and adult Ph- positive ALL in which the break point occurs within the BCR
gene contains only those BCR amino acid residues encoded by its first exon (Hermans et al., 1987, Cell 51:33-40;
Fainstein et al., 1987, Nature 330:386-388). Both P210 and P190 contain all the amino acids of the ABL oncogene except those encoded by its first exon; they exhibit an abnormal tyrosme kmase activity and are strongly
autophosphorylated in vitro (Konopka et al., 1984, Cell
37:1035-1042; Kloetzer et al., 1985, Virology 140:230-238; Chan et al., 1987, Nature 325:635-637; Clark et al., 1987; Kurzrock et al., 1987, Nature 325:631-635). Although the presence of the Ph chromosome is used as a diagnostic marker and the BCR/ABL fusion protein is invariably found in Ph-positive patients, very little is known about the direct role of BCR/ABL in the pathogenesis of leukemia.
2.2. TRANSGENIC ANIMALS
The term "transgenic animals" refers to non-human animals which have incorporated a foreign gene into their genome; because this gene is present in germline tissues, it is passed from parent to offspring. Exogenous genes are introduced into single-celled embryos (Brinster et al.,
1985, Proc. Natl. Acad. Sci. U.S.A. 82:4438-4442).
Transgenic mice have been shown to express globin (Wagner et al., 1981, Proc. Natl. Acad. Sci. U.S.A. 78:6376-6380), transferrin (McKnight et al., 1983, Cell 34:335-341), immunoglobulm (Brinster et al., 1983, Nature 306:332-336;
Ritchie et al., 1984, Nature 312:517-520; Goodhardt et al., 1987, Proc. Natl. Acad. Sci. U.S.A. 84:4229-4233; Stall et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:3546-3550), human major histocompatibility complex class I heavy and light chain (Chamberlain et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7690-7694), functional human interleukin-2 receptors (Nishi et al., 1988, Nature 331:267-269), rat myosin light-chain 2 (Shani, 1985, Nature 314:283-286),
viral oncogenes (Small et al., 1985, Mol. Cell. Biol.
5:642-648), and hepatitis B virus (Chisari et al., 1985, Science 230:1157-1163) genes, to name but a few.
Rearrangement of immunoglobulin genes has been observed in transgenic mice (Goodhardt et al., 1987, Proc. Natl. Acad. Sci. U.S.A. 84:4229-4233; Bucchini et al., 1987, Nature 326:409-411). Krimpenfort et al. (1987, EMBO J. 6:1673- 1676) generated transgenic mice that showed cell surface expression of HLA-B27 antigen biochemically
indistinguishable from HLA-B27 in human cells by crossing one strain of transgenic mice carrying the HLA-B27 heavy chain gene with mice carrying the transgenic β2
microglobulin gene.
2.2.1. TRANSGENIC ANIMAL MODELS FOR HUMAN CANCERS
Transgenic animals have been observed to express deregulated oncogenes and develop tumors (Stewart et al., 1984, Cell 38: 627-637; Adams et al., 1985, Nature 318: 533-538; Hanahan, 1985, Nature 315: 115-122; Lacey et al.,
1986, Nature 322: 609-612; Palmiter and Brinster, 1986,
Annu. Rev. Genet. 20): 465-499; Cory and Adams, 1988, Annu.
Rev. Immunol. 6:25-48). In particular, a number of
transgenic animals have been developed as model systems for the study of white blood cell disorders.
Lohuizen et al. (1989, Cell 56: 673-682)
developed transgenic mice bearing the pim-1 gene
supplemented with an upstream immunoglobulin murine
leukemia virus long terminal repeat. The pim-1 gene has been found to be activated by proviral insertion in murine leukemia virus-induced T cell lymphomas (Cuypress et al.,
1984, Cell 37: 141-150; Mucenski et al., 1987, Oncogene
Res. 2 : 33-48). Between five and ten percent of the transgenic mice developed by Lohuizen et al. were observed to develop T cell lymphomas before 7 months of age, and
more frequently when newborn mice were infected with murine leukemia virus.
Knight et al. (1988, Proc. Natl. Acad. Sci.
U.S.A. 85: 3130-3134) developed transgenic rabbits bearing the rabbit C-MYC oncogene fused with the rabbit
immunoglobulin heavy chain gene enhancer. The transgenic rabbits were observed to develop what appeared to be an oligoclonal lymphocytic leukemia by the age of 17 to 21 days. Interestingly, mice bearing a similar transgene were observed to develop B cell lymphomas at a later stage ofdevelopment (Adams et al., 1985, Nature 318: 533-538).
With regard to the BCR/ABL gene fusion associated with the Philadelphia chromosome, a BCR/ABL bearing retrovirus has been observed to transform immature
B cells only after prolonged periods of cell culture
(McLaughlin et al., 1987, Proc. Natl. Acad. Sci. U.S.A. 84:
6558-6562; Young and Witte, 1988, Mol. Cell. Biol. 8 :
4079-4087); however, BCR/ABL was found not to transform NIH 3T3 fibroblasts (Daley et al., 1987, Science 237: 532-535).
Hariharan et al. (1989, Moi. Cell. Biol. 9: 2798-2805) developed transgenic mice bearing a synthetic BCR/abl gene comprising BCR and a viral abl gene (v-abl) fragment which lacks the second and a portion of the third exon, of the murine cellular abl (c-abl) gene and which also carries a substantial internal deletion. (Hariharan et al., 1988,
Oncogene Res. 3: 387-399). The synthetic fused gene was combined with either the immunoglobulin heavy chain gene enhancer or a portion of the long terminal repeat from myeloproliferative sarcoma virus (Franz et al., 1986, Proc.
Natl. Acad. Sci. U.S.A. 83: 3292-3296); some of the mice developed lymphomas, but not leukemias, after a variable latent period.
3. SUMMARY OF THE INVENTION
The present invention relates to non-human transgenic animals which contain a transgene comprising a BCR/ABL gene fusion and which develop leukemia. In particular embodiments of the present invention, the transgenic animals may exhibit a rapid induction of acute leukemia or, alternatively, a chronic myelogenous-type leukemia.
The transgenic animals of the invention carry a transgene which comprises a 5' portion of BCR exons and a 3' portion of ABL exons. In a preferred embodiment of the invention, the ABL nucleotide sequences comprise human ABL nucleotide sequences. In alternate embodiments, the transgene comprises non-human abl gene sequences. In further preferred embodiments of the invention, the
transgene comprises either at least a complete third exon or a portion of the second exon of the ABL gene. In a specific embodiment of the present invention, the
transgenic animals carry a transgene comprising the first exon of the BCR gene as well as at least one exon from the
Mbcr region and exons 2 through 11 of the ABL gene. In a preferred specific embodiment of the present invention, the transgenic animals carry a transgene comprising the first exon of the BCR gene and exons 2 through 11 of the ABL gene.
The present invention offers the advantage of providing, for the first time, a non-human transgenic animal model system which carries the BCR/ABL gene fusion characteristic of the Philadelphia chromosome; transgenic animals of the invention have been found to develop
leukemia in a manner directly analogous to the clinical progression of chronic myelogenous leukemia (CML) and/or acute lymphoblastic leukemia (ALL) in humans. This model system for human leukemia may be valuable in obtaining a
better understanding of CML and ALL and in developing effective therapeutic regimens.
3.1. DEFINITIONS
ABL: the human ABL oncogene using standard
5nomenclature. Unless specified, ABL as used herein may refer to human or non-human nucleotide sequence.
abl: non-human oncogene corresponding to ABL.
BCR: the Breakpoint Cluster Region gene.
c: cellular.
Mbcr: the major breakpoint cluster region in which are located several of the breakpoints characteristic of the Philadelphia chromosome of CML.
Transgenic animal: a nonhuman animal which has incorporated a foreign gene into its genome.
Transgene=transgenιc sequence: a foreign gene or recombinant nucleic acid construct which has been incorporated into a transgenic animal,
v: viral.
4. DESCRIPTION OF THE FIGURES
Figure 1. Expression of P190 BCR/ABL. Two clones (lanes 1 and 2) transfected with P190/BCR produce a P190 protein, that is active in an in vitro
autophosphorylation assay, whereas a third clone (lane 3) is negative. An arrow points to the P190 and to the P210 produced in K562 (lane 4).
Figure 2. P190-producing BCR/ABL construct as comprised in pALMP. Boxed areas indicate the position of coding sequences; the location of the MT promoter, BCR exon
1, ABL exon 2 and the main body of ABL exons is as
indicated below the map. The location of the probe used in
Figure 3 (0.6 XhBg) is indicated above the map with a cross-hatched box. The arrows above the map point to the
approximate locations of oligonucleotide primers, "ALL E" and "ALL F" (Kawasaki et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 85:5698-5702). B=BamHI; Bg=BglII, E=EcoRI;
H=HindIII; K=KpnI; S=SalI; Xh=XhoI.
Figure 3. Southern blot analysis of transgenic mice. Numbers above the lanes refer to the mice described in the text. DNAs were digested with BamHI. A λ/Hindlll marker is shown to the left. C- = negative control; C+ = positive control with 0.1 ng cloned DNA construct added in the digestion.
Figure 4. Expression of the P190 BCR/ABL construct. RNAs used include those from heart, muscle, brain and spleen of mouse #509 (lanes 1-4); NIH 3T3 cells (lanes 6 and 8); control non-transgenic #417 RNA (lanes 7 and 10), NIH 3T3 cells transfected with P190/BCR (lane 9) and RNA from transgenic #418 (lane 11).
Figure 5. Pathology of CML, blast crisis mice. A. Gross anatomical picture of mouse #418. Note the presence of prominent tumor masses associated with the lymph nodes and soft tissues of the neck. B. Central nervous system of mouse #536. Note the extensive tumor involvement in the subarachnoid space of the brain (x120, hematoxylin and eosin [H and E]). C. Medium power view of soft tissue-associated tumor in mouse #418. Note the total involvement of soft tissue with neoplastic myeloid cells which are predominantly composed of myeloblasts and
promyelocytes with varying lesser numbers of myelocytes and metamyelocytes (x640, H and E). D. Medium power view of leukemia-involved peripheral blood with leukemic myeloid cells which are predominantly composed of segmented
polymorphonuclear neutrophils (PMNs) and lesser numbers of more undifferentiated forms (x640, H and E).
Figure 6. Pathology of ALL mice. Medium power view of involved bone marrow from mouse #509. Note the
extensive involvement of marrow with primitive lymphoblasts with scant cytoplasm (x580, H and E). B. Medium power view of peritrabecular soft tissue. Note the extensive involvement of bone-associated soft tissue with primitive, neoplastic lymphoblasts which are invading between skeletal muscle fibers (x600, H and E). C. Medium power view of peripheral blood from mouse #538. Note the extensive involvement with primitive, neoplastic lymphoblasts which demonstrate primitive nuclear chromatin and scant cytoplasm (x620, Wright-Giemsa). D. higher power view of the same peripheral blood from mouse #538. Note the presence of a mitotic figure (x780, Wright-Giemsa).
Figure 7. Diagram of (a) BCR gene; (b) c-ABL gene; (c) a BCR/ABL gene fusuion on a Philadelphia
chromosome from a patient with CML; and (d) a BCR/ABL gene fusion on a Philadelphia chromosome from a patient with ALL
(see Kurzrock et al., 1988, N. Engl. J. Med. 319:990-997).
Figure 8. The BCR/ABL c18(der) construct as comprised in pCLMP. The open box represents the BCR gene coding sequences; the solid boxes represent ABL coding sequences. A = Aa + II; B = BamHI; E = EcoRI.
5. DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to transgenic non-human animals which carry a BCR/ABL transgene and whichmay serve as animal models of leukemia in humans. For purposes of clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the following subsections:
(i) BCR/ABL Recombinant Nucleic
Acid Constructs
(ii) Generation of Transgenic Animals
(iii) Utility of the Invention.
5.1. BCR/ABL RECOMBINANT NUCLEIC ACID CONSTRUCTS
Recombinant BCR/ABL constructs may be produced using any method known in the art. BCR and ABL genes, or portions thereof, may be derived from human or non-human (abl) sources. BCR or ABL gene sequences may be obtained from the same species intended to serve as the transgenic host, although it may be preferable to use human BCR and ABL gene sequences to create a model for the gene product associated with human disease.
The ABL gene may be obtained from constructs which have been the subjects of publication and are
available among those skilled in the art, such as the construct described in Heisterkamp et al. (1983, J. Mol. Appl. Gen. 2: 57-68) or pALMP or pCLMP constructs of the present invention. The available ABL sequences may also be used to identify additional clones bearing ABL sequences in genomic DNA or cDNA libraries using standard hybridization techniques such as the method set forth by Benton and Davis (1977, Science 196:180) for bacteriophage libraries and
Grunstein and Hogness (1975, Proc.Natl.Acad.Sci. U.S.A
72:3961-3965) for plasmid libraries, or may be used to clone ABL sequences using polymerase chain reaction (PCR) technology (Saiki et al., 1985, Science 230:1350).
Similarly, BCR sequences may be obtained from publicly available constructs or using the pALMP or pCLMP constructs of the present inventioo in conjunction with standard colony hybridization or PCR techniques.
Alternatively, a naturally occurring BCR/ABL fused gene may be cloned from cells carrying the
appropriate translocation for use according to the present invention, using standard techniques. The BCR and ABL sequences utilized may represent genomic DNA or cDNA sequences.
Portions of the BCR and ABL genes may be linked together using any technique known in the art, including the ligation of compatible restriction endonuclease
fragments. According to the present invention, the fused BCR/ABL construct may comprise the first BCR exon and either the entire third exon of ABL or a portion of its second exon (see Figure 7). If the ABL sequences are derived from human c-ABL sequences, the BCR/ABL construct may contain one or more ABL exons.
In preferred embodiments of the invention, the BCR/ABL gene fusion is engineered to resemble BCR/ABL gene fusions produced by naturally occurring translocations and found in association with Philadelphia chromosomes. For example, and not by way of limitation, the fused BCR/ABL gene may be engineered to resemble the BCR/ABL fusion found on Philadelphia chromosomes in patients with CML, and may preferably comprise the first BCR exon as well as at least one exon from the Mbcr region and the second through eleventh ABL exons of the ABL gene or a functional portion therof.A functional portion of the ABL gene is construed to refer to a portion of the ABL gene which encodes a protein which retains tyrosine kinase activity. A specific example of a construct which resembles a BCR/ABL fusion associated with CML is comprised in construct pCLMP of the prsent invention. Alternatively, and not by way of limitation, the fused BCR/ABL gene may be engineered to resemble the
BCR/ABL gene frequently associated with Philadelphia chromosome positive ALL, which includes the first BCR exon and the second through eleventh ABL exon; accordingly, the constructs of the invention may comprise one BCR exon and the second through eleventh ABL exons, or a functional portion thereof. A specific example of a construct which resembles a BCR/ABL fusion associated with ALL is comprises in construct pALMP of the present invention. According to
the invention, when constructs which resemble naturally occurring BCR/ABL fusions associated with CML are used to create transgenic animals, the resulting transgenic animals may develop a leukemia similar to CML, and when constructs which resemble naturally occurring BCR/ABL fusions
associated with ALL are used to create transgenic animals, the resulting transgenic animals may be likely to develop a leukemia similar to ALL.
The BCR/ABL gene fusion of the invention is preferably engineered to be under the control of a suitable promoter sequence. Any promoter sequence known in the art may be used, but it is preferable that the promoter used is not particularly active during embryonic development, as such promoters, including the BCR promoter, have been
associated with a high mortality rate for transgenic
embryos. For this reason, strong viral promoters, such as those found in retroviral long terminal repeats, are
preferably not used. Particularly useful promoters would exhibit relatively low levels of expression during
embryonic development. Suitable promoters would include inducible promoters, including, but not limited to, the metallothionine promoter (Brinster et al., 1982, Nature
296: 39-42), the heat shock protein promoter, elastase I gene control region which is active in pancreatic acinar cells
(Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986,
Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald,
1987, Hepatology 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell38:647-658; Adames et al., 1985, Nature 318:533-538;
Alexander et al., 1987, Mol. Cell. Biol. 2:1436-1444), mouse mammary tumor virus control region which is active in
testicular, breast, lymphoid and mast cells (Leder et al.,
1986, Cell 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel.
1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58); alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al, 1987, Genes and Devel. 1:161-171), beta-globin gene control region which is active in myeloid cells (Mogram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48: 703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, Nature 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378).
The BCR/ABL gene constructs may be cloned using any method known in the art. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, cosmids, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors inclde, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as PBR322, pVCs or Bluescript® (Stratagene) plasmid derivatives. Recombinant molecules may be
introduced into host cells via transformation,
transfeetion, infection, electroporation, etc.
Once a BCR/ABL construct has been generated, it may preferably be tested to determine whether it results in a functional gene product. For example, the BCR/ABL construct may be co-transfected into a suitable cell line (including but not limited to the Rat-2 cell line) together with an appropriate reporter gene (such as, but not limited
to, thymidine kinase activity, resistance to antibiotics, including G418 etc.). Transfected cells may then be selected and tested for expression of a BCR/ABL gene product. For example, RNA may be harvested from the cells and tested for the presence of a BCR/ABL mRNA transcript using either standard Northern blot techniques or
polymerase chain reaction using appropriate oligonucleotide primers (Kowasaki et al., 1988, Proc. Natl. Acad. Sci.
U.S.A. 85: 5698-5702). Preferably, the transfectants may be tested for acquisition of BCR/ABL associated tyrosine kinase activity using a standard in vitro phosphorylation assay, such as that described in Fainstein et al. (1987, Nature 330: 386-388) or tested for reactivity with anti-ABL antiserum, such as that described in Stam et al. (1987,
Mol. Cell. Biol. 7: 1955-1960). In addition, protein may be harvested from the transformed cells and analyzed by
SDS-polyacrylamide gel electrophoresis and/or Western blotting techniques using, for example, anti-ABL antiserum (Stam et al., supra) to determine whether a protein of appropriate molecular weight has been encode by the BCR/ABL construct. If it appears that the BCR/ABL construct is adequately expressed in the transfected cell line, the construct may then be used to produce transgenic animals.
5.2. GENERATION OF TRANSGENIC ANIMALS
The recombinant DNA molecules of the invention may be introduced into the genome of non-human animals using any method for generating transgenic animals known in the art.
In general, the scheme presently employed to produce transgenic mice involves the following: male and female mice, from a defined inbred genetic background, are mated at midnight. Twelve hours later, the female is sacrificed and the fertilized eggs are removed from the
uterine tubes. At this time, the pronuclei have not yet fused and it is possible to visualize them in the light microscope. Foreign DNA is then microinjected (100-1000 molecules per egg) into a pronucleus. Shortly thereafter fusion of the pronuclei (a female pronucleus or the male pronucleus) occurs and, in some cases, foreign DNA inserts into (usually) one chromosome of the fertilized egg or zygote. The zygote is then implanted into a pseudo-pregnant female mouse (previously mated with a vasectomized male) where the embryo develops for the full gestation period of 20-21 days. The surrogate mother delivers these mice and by four weeks the pups are weaned from the mother. To test these mice for the presence of foreign DNA, a portion of the tail (a dispensable organ) is removed and the DNA extracted. DNA-DNA hybridization (in a dot blot, slot blot or Southern blot test) is employed to determine whether the mice carry the foreign DNA. Of the eggs injected, on average 10% develop properly and produce mice. Of the mice born, on average one in four (25%) are transgenic for an overall efficiency of 2.5%. Once these mice are bred they pass along the foreign gene in a normal (Mendelian) fashion linked to a mouse chromosome. Mating two homozygous mice with the transgenic DNA means 100% of the offspring carry two copies of the transgene.
When this is done it is common that the mice carry tandemly repeated copies of the foreign gene (from 1-80 copies) at one chromosomal location or site.
The present invention is not limited to any one species of animal, but provides for any non-human animal species which may be appropriate. For example, mice, guinea pigs, rabbits and pigs, sheep, cows, goats, and horses, to name but a few, may provide useful transgenic systems.
Likewise, any method known in the art may be used to produce transgenic animals, including but not limited to,
microinjection, cell gun, transfection of DNA, and
electroporation.
It is preferable to remove prokaryotic sequences from eukaryotic sequences prior to the introduction of eukaryotic sequences into the single-celled embryos, using techniques
(e.g. gel electrophoresis) known in the art.
5.3. UTILITY OF THE INVENTION
The present invention relates to the production of non-human transgenic animals that may serve as
clinically accurate models for human diseases which have been associated with BCR/ABL gene fusions resulting from chromosomal translocation, including Philadelphia
chromosome positive CML and ALL. The transgenic animals of the invention provide, for the first time, an animal model system in which the BCR/ABL transgene results in the
development of leukemia. As illustrated in Example Section
6, infra, in a specific embodiment of the invention, in which transgenic animals are produced which carry a BCR/ABL transgene that resembles the BCR/ABL gene fusion associatedwith Philadelphia chromosome positive ALL, the transgenic animals of the invention were observed to develop acute leukemia resembling ALL at an age comparable to the average age of onset of human ALL.
By serving as an accurate model for CML and ALL, the transgenic animals of the invention provide a useful system for the development of therapeutic programs for these diseases, including both chemotherapeutic and
immunotherapeutic modalities. Furthermore, the transgenic animals of the invention can be used to advance basic research in these diseases.
According to an alternate embodiment of the invention, transgenic animals which carry a BCR/ABL
transgene may be produced, and the bone marrow of these transgenic animals may be harvested and then used to
repopulate the bone marrow of another animal, the bone marrow of which has been destroyed (e.g. by x-ray
irradiation). Animals produced by this method may also be used as effective models of CML or AML, and offer the advantage of not expressing BCR/ABL in non-hematologic tissues.
Similarly, the BCR/ABL constructs may be
introduced into bone marrow cells, including, but not limited to, embryonic stem cells, of a non-human animal using any method known in the art (including transfection, transformation, infection, electroporation, microinjection or cell gun) in vivo or in vitro, and the cells may then be re-introduced so that they may re-populate the bone marrow of animal. The resulting animal should contain BCR/ABL sequences in the genomic DNA of some but not all of its cells, and therefore may be considered a chimeric animal.
In addition, a useful model for the development of leukemia may be produced by generating a transgenic animal in which the BCR/ABL transgene is under the control of an inducible promoter. In a preferred embodiment of the invention, the BCR/ABL transgene may be under the control of the metallothionine promoter, such that when the
transgenic animal is exposed to heavy metals, the
expression of BCR/ABL may be induced and leukemia may result.
Furthermore, the transgenic animals of the invention may be used as sources of cells and tissues which may be grown in culture and which may be useful in the study of human leukemia.
6. EXAMPLE: GENERATION OF BCR/ABL TRANSGENIC
MICE WHICH DEVELOP PHILADELPHIA CHROMOSOME POSITIVE ACUTE LEUKEMIA
6.1. MATERIALS AND METHODS
6.1.1. AUTOPHOSPHORYLATION ASSAY
Cellular extracts (106 cells) were prepared as described (Fainstein et al., 1987, Nature 330:386-388); in vitro phosphorylation assays were performed as described in Fainstein et al. (1987, Nature 330:386-388) using a
previously described anti-ABL antiserum (Stam et al., 1987, Mol. Cell Biol. 7:1955-1960).
6.1.2. DNA CONSTRUCTS AND TRANSGENIC MICE
The construct was made in several steps. A 1.8 kb Bglll-Kpnl fragment from an ABL cosmid clone
(Heisterkamp et al., 1983, J. Mol. Appl. Gen. 2:57-68) containing exon 2 was isolated; a 5 kb Kpnl-EcoRI cDNA fragment containing all 3' ABL exons was ligated with the first fragment into pSK digested with BamHI and EcoRI. A genomic 7 kb EcoRI DNA fragment containing the first BCR gene exon was inserted into pSK and clones containing a 5' Clal and 3' Notl sites were isolated. The 5' Clal- 3' Notl BCR gene fragment was ligated with the 5' Notl - 3' Clal ABL fragment into pSK digested with Clal. This construct contained all coding information for P190 under control of the BCR gene promoter. To replace this promoter with that of the mouse metallothionine gene, plasmid mMT-1 was digested with Sstl and Bglll and the 200 bp MT promoter fragment was inserted into pSK digested with Sstl and
BamHI; this plasmid was opened at the 3' end of MT with a Smal x Sall digest. A 0.7 kb fragment of the first BCR gene exon, from Eagl to Sail, was blunted at the Eagl site and inserted into this plasmid. The resulting promoter fragment has 13 nucleotides of the BCR gene 5' to its
initiator methionine codon. A Clal-Sstl linker was
inserted into the plasmid at the 5' end and the entire promoter fragment was isolated as a 5' Clal - 3' Xhol fragment (an Xhol site is present 5' to the Sall site in the first BCR gene exon). This was ligated with a 9 kb 5'
Xhol - 3' Clal BCR/ABL fragment into pSK. Vector sequences
(3 kb) were separated from the insert (14 kb) by an Sstll digestion; inserts were purified by electrophoresis on low melting point agarose gels, phenol/sodium acetate
extractions (Heinsterkamp et al., 1983, J. Mol. App. Gen. 2:57-68) and passage over an elutip-D (Schleicher and
Schuell) column. Microinjections into one-cell fertilized eggs were performed essentially as described (Hogan et al., 1986 in "Manipulating the Mouse Embryo", Cold Spring Harbor
Press, Cold Spring Harbor, NY). Southern blots were with
10 ug of DNA; blotting and hybri.di.zati.on were as described; a 0.6 kb Xhol-Bglll fragment from the first exon of the BCR gene was used as probe.
6.1.3. RNA ISOLATION AND PCR ANALYSIS
RNAs were isolated using guanidine- thioisocyanate (Chomczynski and Sacci, 1987, Anal. Biochem. 162:156-159). The first strand was synthesized using
MoMuLV reverse transcriptase and oligonucleotide "ALL F" as described in Kawasaki et al. (1988, Proc. Natl. Acad. Sci.
U.S.A. 85:5698-5702). The polymerase chain reaction was performed as described in the accompanying manuscript using oligonucleotides "ALL E" and "ALL F" (Kawasaki et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:5698-5702). Samples were hybridized to oligonucleotide "ALL G" (Kawasaki et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:5698-5702).
6.1.4. HISTOPATHOLOGY
Complete autopsies were performed. Mice were anesthesized prior to all procedures possibly involving pain or discomfort. Mice were sacrificed using cardiac puncture; peripheral blood samples were collected from the tails of anesthesized mice. Tissue sections were fi.xed for
2 hours in a mixture of 10% formalin and 90% B5 (20 g HgCl and 4.2 g NaAc [anhydrous] in 300 ml) and stored in 70% ethanol. Peripheral blood and bone marrow smears were stained with Wright-Giemsa stain and evaluated
morphologically. White blood cell (WBC) counts were performed with a hemocytometer.
6.2. RESULTS
6.2.1. THE P190 CONSTRUCT
In initial experiments, a DNA construct encoding
P190 under control of the human BCR promoter was tested. After co-transfection of this construct with the TK
(thymidine kinase) gene into Rat-2 cells in culture, colonies were picked and assayed for P190
autophosphorylation activity. Two of three lines tested
(Figure l, lanes 1 and 2) produced substantial amounts of active P190 although the level was lower than that found in the P210-producing cell line K562 (lane 4). The two P190- producing lines both exhibited a transformed phenotype (not shown), which was evident immediately after selection on
HAT medium. These experiments established that the
construct encoded a functional protein.
After microinjection of this P190 construct into fertilized one-cell embryos, reimplantation and birth of pups, no transgenic progeny were obtained. To circumvent the possibility that its expression is lethal during embryogenesis a new construct was made, identical to the first except that the BCR promoter was replaced by the
mouse metallothionine-1 (MT) promoter. This promoter was chosen, because it can be considered "housekeeping" in that it is expressed in nearly all tissues and, in addition, is inducible (Brinster et al., 1982, Nature 296:39-42). The final construct (Figure 2) consists of a segment of the MT promoter, from nucleotide -153 to +68 (Stuart et al., 1984, proc. Natl. Acad. Sci. U.S.A. 81:7318-7322), joined to the first exon of the BCR gene. The construct further contains segments of BCR intron 1, the pSK polylinker, a segment of ABL intron 1, exon 2, intron 2 and the remaining ABL coding sequences.
6.2.2. TRANSGENIC P190 MICE EXPRESS THE TRANSGENE
Using this construct, a total of 60 progeny mice were obtained; of these, 10 (16.6%) were found to be transgenic. Southern blot analysis on tail DNAs next to cloned DNA reference standards of known quantities (not shown) indicated that transgene copy numbers varied from an estimated 1 to 10 copies (see table 1). Multiple-copy transgenes appeared to consist of tandem, head-to-tail arrays of the construct (Figure 3).
RNAs isolated from two animals (#418 and #509) which had exhibited distinct pathological symptoms (see below) were used to evaluate expression of the transgene.
Since RNA was isolated post-mortem from the leg (including marrow, bone, blood and muscle) of animal #418, which had died, it was unsuitable for Northern blot analysis.
Therefore, expression was examined using previously
described (Kawasaki et al., 1988, Proc. Natl. Acad. Sci.
U.S.A. 85:5698-5702) oligonucleotide primers (see Figure
2), reverse transcriptase and the polymerase chain
reaction. Although this method is not quantitative, it will allow the evaluation of the presence or absence of a transcript. The oligonucleotides should amplify a cDNA
fragment of 307 bp in cells containing the 7.0 kb BCR/ABL chimeric mRNA.
In RNA isolated from NIH 3T3 cells transfected with the P190/MT construct and the original P190/BCR construct this method detected the 307 bp fragment (Figure 4, lanes 5 and 9). No signal is evident in untransfected
NIH 3T3 control RNA (lanes 6 and 8). This indicates that the construct produces mRNA in the absence of intentional induction of the promoter with heavy metals. In the RNA of mouse #418, the 307 bp fragment is also clearly present
(Figure 4, lane 11). Control RNA isolated post-morten from a non-transgenic sibling (#417, lane 7 and 10) showed no signal. RNA was extracted from spleen, brain, heart, and muscle of mouse #509: expression was found in all these tissues (Figure 4, lanes 1-4).
6.2.3. BCR/ABL TRANSGENIC MICE RAPIDLY
DEVELOP ACUTE LEUKEMIA
To date of the ten transgenic animals, eight have died and two remain alive. Three animals (#418, 536and 530) ranging in age from 10-13 days were found dead before peripheral white blood cell counts could be
performed (Table 1). Four animals (#509, 510, 538,
peripheral blood. The remaining animal, a pregnant female (mouse #528), died at 58 days while giving birth. It had aterminal blood cell count of 2.9 x 109/L. A small but significant percentage (approximately 5%) of peripheral blood white cells were lymphoblasts. All eight animals which died were autopsied and examined histopathologically. Interestingly, six animals (#530, 509, 510, 538, 529 and528) were diagnosed as having ALL, while the remaining two ( #418 and 536 , both of which were found dead) were
diagnosed after autopsy as having CML, in blast crisis.
6.2.4. PATHOLOGY OF LEUKEMIC MICE
The hematopathologic features of these two leukemic processes are further detailed and summarized in
Table 2. More specifically, mouse #418 demonstrated the presence of greatly enlarged neck masses (see Figure 5A), which proved histopathologically to be either lymph nodes and/or subcutaneous tissue involved with neoplastic
myelogenous leukemia cells (see Figure 5C). The neck mass-associated leukemia cells were composed predominantly of primitive myeloid-type blasts (myeloblasts) with varying smaller numbers of promyleocytes, myelocytes and
metamyelocytes (see Figure 5C). These morphologic findings were also observed in bone marrow. In contrast to bone marrow and neck masses, peripheral blood from mouse #418, although markedly leukemic (see hepatic vein, Figure 5D), demonstrated a predominance of segmented polymorphonuclear neutrophils (PMNs) with lesser numbers of more
undifferentiated myeloid forms. Mouse #536, although not demonstrating enlarged neck masses, had similar morphologic findings (predominantly myeloid-type blasts with lesser numbers of more differentiated granulocytic forms) in its bone marrow. In addition, #536 demonstrated marked
leukemic infiltration of the central nervous system (Figure
5B). Taken together, mouse #418 and 536 were diagnosed as having CML, blast crisis (myeloid type).
Abbreviations used: WBC = peripheral white blood cell count; ND = not done; NA = not applicable; CML = chronic myelogenous leukemia; ALL = acute lymphoblastic leukemia; LL = lymphoblastic lymphoma.
2
Animals 418, 536 and 530 were found dead; animals 509, 510, 528, 529 and 538 were sacrificed when moribund. 3
Preterminal WBC's: WBC of animal 510 (x10 9/L) = 22.5 on day 21 and 47.5 on day 25; WBC of animal 529
(x109/L) = 13.2 on day 28 and 297 on day 41; WBC of animal 538 (x10 9/L) = 14.1 on day 18, 20.1 on day 24 and 29.8 on day 37; WBC of animal 528 (x109/L) = 18.1 on day 28, 12.8 on day 41.
4
Although mouse 523 and 540 are alive with normal WBC counts, a small but significant percentage (3-5%) of peripheral blood white cells were lymphoblasts. in contrast, mouse #509, 530, 510, 538, 529 and
528 were observed to have bone marrows which were
predominantly replaced with primitive lymphoblasts (see Figure 6A). In addition, all six of these mice
demonstrated peritrabecular invasion of neoplastic
lymphoblasts into the surrounding skeletal muscle- containing soft tissues (Figure 6B). All mice
morphologically demonstrated peripheral blood involvement, with four mice (#509, 510, 538, 529) exhibiting markedly elevated peripheral blood WBC counts, which were
predominantly composed of neoplastic, primitive
lymphoblasts (Figure 6C and 6D). Both the splenic white and red pulp were extensively involved with neoplastic lymphoblasts in mice #509, 510, 538 and 529. Taken
together, five mice (#530, 509, 510, 538, 529) were easily diagnosed as having ALL. Mouse #528, although having morphologically detectable leukemia cell involvement of peripheral blood and spleen, had extensive bone marrow and lymph node involvement as well as histopathologically detectable subarachoid involvement of the central nervous system with neoplastic lymphoblasts. This mouse was therefore diagnosed as having acute lymphoblastic
leukemia/lymphoblastic lymphoma (LL). In addition, the involvement of the thymus was not found in any of these six animals.
1
Abbreviations used: CML = chronic myelogenous
leukemia; PMNs = polymorphonuclear neutrophils; ALL = acute lymphoblastic leukemia; Ig = immunoglobulin.
6.2.5. ACUTE LYMPHOBLASTIC LEUKEMIA
IS PREDOMINANTLY NON-CLONAL
Preliminary genotype analysis was performed on leukemia-involved splenic tissue obtained from four ALL animals (#509, 510, 538 and 529 [see above]). Phenotypic analysis on available frozen tissue spleen sections from animals #509 and 510 demonstrated positive immunostaining for the B220 antigen on neoplastic lymphoblasts. Since B220 antigen is normally found on mouse pre-B cells as well as on more mature B cells (Coffman, 1983, Immunol. Rev. 69:5-23) it was of importance to determine if the B220+ lymphoblasts had undergone clonal rearrangement(s) of their immunoglobulin genes. Southern blot analysis of genomic DNA from the spleens of these two (#509 and 510) as well as from a third (#538) animal demonstrated germline
configurations for both the IgH (heavy chain) and kappa (light chain) genes (data not shown). In contrast, genomic DNA from the spleen of animal #529 showed the presence of a minor clone of pre-B cells (two faintly rearranged bands with the IgH (J-H) probe and unrearranged [germline] bands with the kappa light chain probe). The T-cell receptor β chain locus had a germline configuration in all four animals. In summary, preliminary phenotypic and/or
genotypic evaluation of the ALL Mice is most likely
consistent with the presence of a polyclonal population of neoplastic pre-B lymphoblasts.
6.3. DISCUSSION
In the experiments described herein, we have generated ten transgenic BCR/ABL P190 mice, eight of which died or were moribund with acute leukemia between 10 and 58 days after birth. Remarkably, two animals were diagnosed as having blast crisis CML while the remaining six had acute lymphoblastic leukemia (ALL). In addition to being extremely rapid in onset, both morphologic types of
leukemia closely resembled the corresponding human disease.
In initial experiments, we have attempted to generate transgenic mice using BCR/ABL P210 or P190
constructs under control of the BCR gene promoter; however, live transgenic progeny were never obtained with either construct. In the construct used here, the expression of P190 was under control of a fragment of the MT promoter, which apparently was expressed late or not at all during embryogenesis . The MT promoter as a whole has been
frequently used by others to generate transgenic mice;
varying levels of spontaneous or inducible expression have been found in different tissues (for example, see Iwakura et al., 1988, EMBO J. 7:3757-3762). Upon transfection of
NIH 3T3 cells, our construct had a basal level of
spontaneous expression. In view of these data, it is probable that a low level of spontaneous transcription must have occurred in the transgenic mice. In addition, there appears to be some correlation between transgene copy number and severity or course of the disease, as the only two animals alive to date have a single copy of the
transgene (see Table I). It is interesting that both mice with single transgenic copies, although alive with normal WBC counts, have a small but significant percentage of
circulating lymphoblasts on peripheral blood smears. It appears that the transgene was expressed in the two animals tested representing both types of acute leukemia (CML blast crisis and ALL), although we cannot quantitatively compare the levels in these animals using the PCR/RT method on RNAs of different quality. Transcription was found in the heart, brain, muscle, spleen and liver of mouse #509.
Although it is possible that these tissues actually
transcribe the transgene, it is more likely that the observed expression originated from infiltrating or bloodvessel leukemia cells. The weak signal seen in the heart RNA prepraration may therefore be due to the fact that the animal was sacrificed by cardiac puncture and removal of blood from this organ.
The BCR gene, which contributes its promoter to the chimeric BCR/ABL gene in human Ph-positive leukemia is not expressed exclusively or in extremely high levels in bone marrow (Collins et al., 1987, Mol. Cell Biol. 7:2810- 2876). The results presented here indicate, indeed, that its promoter is not necessary at all for leukemogenesis.
Instead, it appears that the crucial contribution of the
BCR gene consists of its 5' coding sequences and that its fusion of these sequences to human ABL produces a unique, leukemogenic protein. The properties of this protein must be closely related to its primary structure; recently, mice have been generated which were transgenic for a BCR/v-ABL
P120 (lacking the murine exon 2 and part of exon 3) fused to most of the 5' BCR exons as found in CML. Of the 15 founder animals, three were moribund after 14, 55 and 77 days; the remaining animals were alive at 12 months of age and showed no signs of tumors; the type of malignancy generated by this transgene differs from that found in the present study in that only monoclonal B and T cell
lymphomas were found (Hariharan et al., 1989, Mol. Cell
Biol. 9:2798-2805).
Although it superficially appears that two completely different morphologic types of acute leukemia
(lymphoid and myeloid) were generated in BCR/ABL transgenic mice, previous work in both man and mouse supports a close relationship between B-lymphoid and myeloid cells. It is well known that human chronic myelogenous leukemia often evolves to a pre-B lymphoblast crisis (Bakhsi et al., 1983,
N. Engl. J. Med. 309: 826-831; Vogler et al., 1979, Blood
54:1164-1170). Hematopoeitic cells transformed in vitro by
RAS oncogene-containing retroviruses coexpress pre-B and myeloid cell phenotypes suggesting that a progenitor cell for both B lymphocytes and myeloid cells (primarily
granulocyte [G]/monocytes [M]) exists (Holmes et al., 1986,
J. Exp. Med. 164:443-457). Further evidence for the existence of a common progenitor cell, termed pro G/M/B, is provided by a variety of in vitro studies which demonstrate differentiation of lymphoid-like progenitor cells into macrophages (Davidson et al., 1988, J. Exp. Med. 168:
389-407; Bauer et al., J. Immunol. 136:4695-4699; Hanecak et al., 1989, Mol. Cell Biol. 9:2264-2268). It is
therefore not surprising that both types of leukemia were observed in BCR/ABL transgenic mice.
Since three of the affected mice died between
10-13 days of age, it is possible that they may have been preleukemic in utero. Four other mice were overtly
leukemic at 21, 28, 38 and 43 days. The remaining mouse had overt leukemia/lymphoma at 58 days. If one considers, that one mouse year is roughly equivalent to 33 human years, the ranges in the ages at death would correspond from 11 months to 5 years in human age. In the human, the majority of children with Ph-positive ALL are pre-B in immunotype (Ribeiro et al, 1987, Blood 70:948-951) and
predominantly appear to have the type of translocation which produces P190 (Heisterkamp et al., 1989, Blood
73:1307-1311). The P190 fusion protein may therefore be involved in a very agressive type of leukemia with an early onset and rapid progression. Indeed, the association of the P190 protein with a more aggressive type of disease is supported by experiments, in which the effects of P190 and P210 on immature lymphoid cells were compared: P190 appears to stimulate the growth of immature lymphoid cells more strongly than the P210 in mouse bone marrow cultures (Mol. Cell Biol. 9:1866-1874).
From the results presented in this study one major conclusion can be drawn: the BCR/ABL hybrid oncogene is causally associated with rapid-onset acute leukemia in transgenic mice which closely mimic the human diseases CML and ALL. Moreover, the rapid induction time, as well as the finding of polyclonality within the presumed pre-B cell population argues that a secondary event was probably not necessary to generate overt leukemia. In this respect, the
P190 found in association with Ph-positive ALL could differ from our mouse model: in Ph-positive, P190 produci.ng ALL, the Ph-chromosome is often neither the sole nor the first chromosomal abnormality present in the leukemic cells of the patients (Dameshek and Gunz, 1983, in "The Nature of
Leukemia", Gunz and Henderson Eds., Grune and Stratton publ. p. 182). Our results indicate however, that the Ph- chromosome alone may be sufficient to cause acute leukemia.
The availability of a mouse model for Ph- positive leukemia should enable us to study many aspects of this disease, from preleukemia to progression, which would otherwise be difficult to follow. In addition, the
availability of a mouse model should also allow a rapid evaluation of therapeutic protocols and chemotherapeutic agents for this type of leukemia.
7. DEPOSIT OF MICROORGANISMS
The following recombinant plasmid was deposited with the Agricultural Research Culture Collection (NRRL) in Peoria, Illinois:
NRRL Accession No. plasmid pALMP B-18563
plasmid pCLMP B-18564
The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.
Agricultural Research Culture Collection
1815 North University Street
Peoria, IL 61604
Date of deposit: November 22, 1989 Accession Number B18564
Claims
1. A non-human transgenic animal which (i) carries a BCR/ABL transgene under the control of a suitable promoter sequence and (ii) which may develop leukemia.
2. The non-human transgenic animal of claim 1 in which the BCR/ABL transgene comprises c-ABL sequence.
3. The non-human transgenic animal of claim 1 in which the BCR/ABL transgene comprises human c-ABL
sequence.
4. The non-human transgenic animal of claim 1 in which the BCR/ABL transgene comprises one exon of the BCR gene and a portion of the third exon of the ABL gene.
5. The non-human transgenic animal of claim 1 in which the BCR/ABL transgene comprises one exon of the BCR gene and the second exon of the ABL gene.
6. The non-human transgenic animal of claim 2 in which the BCR/ABL transgene comprises one exon of the BCR gene.
7. The non-human transgenic animal of claim 2 in which the BCR/ABL transgene comprises one exon of the BCR gene and one exon of the Mbcr region.
8. The non-human transgenic animal of claim 3 in which the BCR/ABL transgene comprises one exon of the BCR gene.
9. The non-human transgenic animal of claim 3 in which the BCR/ABL transgene comprises one exon of the BCR gene and one exon of the Mbcr region.
10. The non-human transgenic animal of claim 1, 2, or 3 in which the BCR/ABL transgene comprises exons two through eleven of the ABL gene.
11. The non-human transgenic animal of claim 1, 2, or 3 in which the BCR/ABL transgene comprises one exon of the BCR gene and exons two through eleven of the ABL gene.
12. The non-human transgenic animal of claim 1, 2, or 3 in which the BCR/ABC transgene comprises one exon of the BCR gene, one exon of the Mbcr region and exons two through eleven of the ABL gene.
13. A non-human transgenic animal which carries a BCR/ABL transgene under the control of a
metallothionine promoter.
14. A recombinant nucleic acid molecule which can be used to produce a non-human transgenic animal which carries a BCR/ABL transgene under the control of a suitable promoter sequence and which may develop leukemia.
15. The recombinant nucleic acid molecule of claim 14 which comprises one exon of the BCR gene and exons two through eleven of the ABL gene .
16. The recombinant nucleic acid molecule of claim 14 which comprises one exon of the BCR gene, one exon of the Mbcr region, and exons two through eleven of the ABL gene.
17. The recombinant nucleic acid molecule of claim 14, 15, or 16 which is under the control of the metallothionine promoter.
18. The recombinant nucleic acid molecule of claim 14 which is pALMP or a portion thereof as deposited with the NRRL and assigned accession number B-18563 .
19. The recombinant nucleic acid molecule of claim 14 which is pCLMP or a portion thereof as deposited with the NRLL and assigned accession number B-18564 .
20. An animal model system for chronic
myelogenous leukemia comprising a non-human transgenic animal which (i) carries a BCR/ABL transgene under the control of a suitable promoter sequence and (ii) which may develop leukemia.
21. An animal model system for acute lymphoblastic leukemia comprising a non-human transgenic animal which (I) carries a BCR/ABL transgene under the control of a suitable promoter sequence and (ii) which may develop leukemia.
22. An experimental animal in which the bone marrow of the animal has been replaced by bone marrow harvested from a non-human transgenic animal which (i) carries a BCR/ABL transgene under the control of a suitable promoter sequence and (ii) which may develop leukemia.
23. An experimental animal comprising bone marrow cells into which a BCR/ABL gene has been introduced.
24. An experimental animal comprising embryonic stem cells into which a BCR/ABL gene has been introduced.
25. Cells which may be propagated in culture and which are derived from a non-human transgenic animal which (l) carries a BCR/ABL transgene under the control of a suitable promoter sequence and (ii) which may develop leukemia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44006289A | 1989-11-22 | 1989-11-22 | |
US440,062 | 1989-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991007489A1 true WO1991007489A1 (en) | 1991-05-30 |
Family
ID=23747261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/006845 WO1991007489A1 (en) | 1989-11-22 | 1990-11-21 | Bcr/abl transgenic animals as models for philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia |
Country Status (3)
Country | Link |
---|---|
US (2) | US5491283A (en) |
AU (1) | AU6882791A (en) |
WO (1) | WO1991007489A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998053317A1 (en) * | 1997-05-20 | 1998-11-26 | Erasmus Universiteit Rotterdam | Recognition of tumour-specific gene products in cancer |
US6686165B2 (en) | 1997-05-20 | 2004-02-03 | Erasmus Universiteit Rotterdam | Recognition of tumor-specific gene products in cancer |
WO2008023268A2 (en) * | 2006-08-24 | 2008-02-28 | Universidad De Salamanca | Leukemia mouse model conditionally expressing a bcr-abl oncogene |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6882791A (en) * | 1989-11-22 | 1991-06-13 | Children's Hospital Of Los Angeles | Bcr/abl transgenic animals as models for philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia |
US20020160970A1 (en) * | 1996-04-10 | 2002-10-31 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6077697A (en) * | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US20030033617A1 (en) | 1996-04-10 | 2003-02-13 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
DE69735498T2 (en) | 1996-09-26 | 2006-11-09 | The Regents Of The University Of Colorado, Boulder | TRANSGENIC MODEL FOR HEART FAILURE |
ES2334727T3 (en) * | 1997-10-06 | 2010-03-15 | Novartis Vaccines And Diagnostics S.R.L. | RECEIVING PROTEIN CD81 OF HEPATITIS C. |
CN1312274A (en) * | 2000-03-07 | 2001-09-12 | 上海博德基因开发有限公司 | Human BCR protein 10 as one new polypeptide and polynucleotides encoding this polypeptide |
WO2002026946A2 (en) * | 2000-09-28 | 2002-04-04 | Bioriginal Food & Science Corporation | Fad4, fad5, fad5-2, and fad6, fatty acid desaturase family members and uses thereof |
ES2195751B1 (en) * | 2001-11-27 | 2005-04-01 | Universidad De Salamanca (Otri) | TRANSGENIC NON-HUMAN MAMPHERS AS MODELS FOR HUMAN PATHOLOGIES WITH ORIGIN IN STEM CELLS. |
CN101046461B (en) * | 2006-03-29 | 2011-04-13 | 福建医科大学 | Electrochemical sensor and its preparation process and use |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4736866B1 (en) * | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6882791A (en) * | 1989-11-22 | 1991-06-13 | Children's Hospital Of Los Angeles | Bcr/abl transgenic animals as models for philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia |
-
1990
- 1990-11-21 AU AU68827/91A patent/AU6882791A/en not_active Abandoned
- 1990-11-21 WO PCT/US1990/006845 patent/WO1991007489A1/en unknown
-
1993
- 1993-01-14 US US08/003,951 patent/US5491283A/en not_active Expired - Fee Related
-
1995
- 1995-06-05 US US08/463,467 patent/US5849996A/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4736866B1 (en) * | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US4736866A (en) * | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
Non-Patent Citations (9)
Title |
---|
BLOOD, Volume 73, No. 5, issued April 1989, HEISTERKAMP et al., "The bcr Gene in Philadelphia Chromosome Positive Acute Lymoblastic Leukemia", pages 1307-1311. * |
MOLECULAR AND CELLULAR BIOLOGY, Volume 8, No. 10, issued October 1988, YOUNG et al., "Selective Transformation of Primitive Lymphoid Cells by the BCR/ABL Oncogene Expressed in Long-Term Lymphoid of Myeloid Cultures", pages 4079-4087. * |
MOLECULAR AND CELLULAR BIOLOGY, Volume 9, No. 5, issued May 1989, MCLAUGHLIN et al., "Alternative Forms of the BCR-ABL Oncogene have Quantitatively Different Potencies for Stimulation of Immature Lymphoid Cells", pages 1866-1874. * |
MOLECULAR AND CELLULAR BIOLOGY, Volume 9, No. 7, issued July 1989, HARIHARAN et al., "A bcr-v-abl Oncogene Induces Lymphomas in Transgenic Mice", pages 2792-2805. * |
NATURE, Volume 331, issued 07 January 1988, DZIERZAK et al., "Lineage-Specific Expression of a Human B-Globin Gene in Murine Bone Marrow Transplant Recipients Reconstituted with Retrovirus-Transduced Stem Cells", pages 06-11. * |
NATURE, Volume 344, issued 15 March 1990, HEISTERKAMP et al., "Acute Leukemia in bcr/abl Transgenic Mice", pages 251-253. * |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Volume 83, issued December 1986, GOSSLER et al., "Transgenesis by Means of Blastocyst Derived Embryonic Stem Cell Lines", pages 9065-9069. * |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Volume 85, issued May 1988, KNIGHT et al., "Transgenic Rabbits with Lymphocytic Leukemia Induced by the c-myc Oncogene Fused with the Immunoglobulin Heavy Chain Enhancer", pages 3130-3134. * |
THE NEW ENGLAND JOURNAL OF MEDICINE, Volume 319, No. 15, issued 15 October 1988, KURZROCK et al., "The Molecular Genetics of Philadelphia Chromosome-Positive Leukemia", pages 990-998. * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998053317A1 (en) * | 1997-05-20 | 1998-11-26 | Erasmus Universiteit Rotterdam | Recognition of tumour-specific gene products in cancer |
US6610498B1 (en) | 1997-05-20 | 2003-08-26 | Erasmus Universiteit Rotterdam | Recognition of tumor-specific gene products in cancer |
US6686165B2 (en) | 1997-05-20 | 2004-02-03 | Erasmus Universiteit Rotterdam | Recognition of tumor-specific gene products in cancer |
WO2008023268A2 (en) * | 2006-08-24 | 2008-02-28 | Universidad De Salamanca | Leukemia mouse model conditionally expressing a bcr-abl oncogene |
WO2008023268A3 (en) * | 2006-08-24 | 2008-07-31 | Univ Salamanca | Leukemia mouse model conditionally expressing a bcr-abl oncogene |
Also Published As
Publication number | Publication date |
---|---|
US5849996A (en) | 1998-12-15 |
AU6882791A (en) | 1991-06-13 |
US5491283A (en) | 1996-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11317611B2 (en) | Genetically modified non-human animal with human or chimeric PD-L1 | |
Tybulewicz et al. | Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene | |
Heisterkamp et al. | Human bcr-abl gene has a lethal effect on embryogenesis | |
US10945418B2 (en) | Genetically modified non-human animal with human or chimeric PD-L1 | |
Esteban et al. | Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development | |
Vize et al. | Introduction of a porcine growth hormone fusion gene into transgenic pigs promotes growth | |
McCormack et al. | The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development | |
US7858843B2 (en) | Gene disruptions, compositions and methods relating thereto | |
US5849996A (en) | BCR/ABL transgenic animals as models for Philadelphia chromosome positive chronic myelogenous and acute lymphoblastic leukemia | |
US5569824A (en) | Transgenic mice containing a disrupted p53 gene | |
JPS6181743A (en) | Gene transfer animal | |
JP2009534051A (en) | Pre-B cell proliferation and lymphoblastic leukemia / high-grade lymphoma in miR155 transgenic mice | |
JP2005523712A (en) | Human chronic lymphocytic leukemia modeled in mice with targeted TCL1 expression | |
JP2008541781A5 (en) | ||
JPH06503967A (en) | Tumor-susceptible non-human animals | |
Baur et al. | Specificity protein 2 (Sp2) is essential for mouse development and autonomous proliferation of mouse embryonic fibroblasts | |
Yee et al. | Lymphoid and mesenchymal tumors in transgenic mice expressing the v-fps protein-tyrosine kinase | |
WO2021083366A1 (en) | Genetically modified non-human animals with human or chimeric thpo | |
US7525011B2 (en) | Transgenic cancer models in fish | |
US20060130167A1 (en) | Transgenic non-human mammals as models for human pathologies of stem cell origin | |
Joosten et al. | Leukemic predisposition of pSca-1/Cb2 transgenic mice | |
CN111485003A (en) | Construction method and application of retinal vascular disease model | |
JP2001211782A (en) | Tob gene deletion knock out non-human mammal | |
US6642433B1 (en) | Fgl-2 knockout mice | |
US6172278B1 (en) | Ikaros transgenic cells and mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR CA FI HU JP KR LK MC MG MW NO RO SD SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG |
|
NENP | Non-entry into the national phase |
Ref country code: CA |